• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Bioactive Products
    Catalog No. Information
    CFN99731 Glabridin

    Glabridin is a GABAA receptor positive modulator promoting fatty acid oxidation and improving learning and memory, which has antioxidative,anti-inflammatory, antimalarial, estrogen receptor agonism, anti-metastasis, anti-melanogenesis and neuroprotective effects. Glabridin may possess a therapeutic effect on metabolic disorders( such as diabetes and hyperglycemia), by modulating glucose metabolism through AMPK in skeletal muscle cells.
    CFN99670 Catalpalactone

    1. Catalpalactone can inhibit dopamine biosynthesis by reducing tyrosine hydroxylase (TH) and aromatic-l-amino acid decarboxylase (AADC) activities and enhance L-DOPA- induced cytotoxiciy in PC12 cells.
    2. Catalpalactone displays good cytotoxicity activities against two human tumor cell lines(MCF-7,BxPC3).
    3. Catalpalactone exhibits significant inhibitory activity against 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced Epstein-Barr virus early antigen (EBV-EA) activation in Raji cells.
    4. Catapalactone exhibits potent inhibitory effects on lipopolysaccharide-induced NO synthesis in RAW 264.7 cells , with IC50 values of 9.80 microM.
    5. Catalpalactone exhibits high antitermitic activity.
    CFN99972 Ginsenoside Rh3

    Ginsenoside Rh3 is a bacterial metabolite of Ginsenoside Rg5, Rh3 has anti-inflammatory effect in microglia by modulating AMPK and its downstream signaling pathways, it may improve chronic dermatitis or psoriasis by the regulation of IL-1β and TNF-α produced by macrophage cells and of IFN-γ produced by Th cells. Rg5 and Rh3 inhibited acetylcholinesterase activity in a dose-dependent manner, with IC50 values of 18.4 and 10.2 uM, respectively, they may protect memory deficit by inhibiting AChE activity and increasing BDNF expression and CREB activation.
    CFN98645 Hirsutanonol

    1. Hirsutanonol or oregonin as an active ingredient composition for treating atopic dermatitis.
    2. Hirsutanonol shows significant inhibitory effects on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced cyclooxygenase-2 (COX-2) expression in immortalized human breast epithelial MCF10A cells.
    3. Hirsutanonol has potent antioxidant activity, it shows significant free radical scavenging activity and exhibits inhibition effect on the mitochondrial lipid peroxidation.
    4. Hirsutanonol shows potent cytotoxic activities against murine B16 melanoma cells and human SNU-C1 gastric cancer cells.
    5. Hirsutanonol has chemoprotective effect on human lymphocytes DNA.
    6. Hirustenone and hirsutanonol show promising anti-filarial activity both in vitro and in vivo studies.
    CFN90005 Fingolimod hydrochloride

    1. Fingolimod hydrochloride is an oral sphingosine-1-phosphate analogue that was approved by the FDA in 2010 for the treatment of relapsing forms of multiple sclerosis (MS), fingolimod hydrochloride is generally well tolerated but requires diligence in patient selection and monitoring. Additional information is needed regarding risk of infection, malignancy and rebound disease with long-term use of fingolimod.
    2. The gels containing 0.50% fingolimod hydrochloride (FNGL) and FNGL 0.50% plus 6% colloidal oatmeal have potential for the treatment of atopic dermatitis (AD), the presence of colloidal oatmeal may provide additional benefits.
    3. Fingolimod hydrochloride can suppress inflammatory reaction of injured blood vessels and lessen the stenosis of injured blood vessels by regulating cyclooxygenase 2 and prostaglandin E2 mRNA expression using sphingosine1-phosphate receptor 1.
    4. Fingolimod hydrochloride , a pak1 activator, can inhibit astemizole-induced hypertrophy and cytotoxicity in H9c2 cells, suggests that antihistamine-induced cardiac adverse effects are associated with pak1 expression and function.